The Food and Drug Administration (FDA) has approved a new presentation of Selarsdi ™ (ustekinumab-aekn), a biosimilar to Stelara ® (ustekinumab), expanding the product’s indications to include ...

Adding albumin to PN solutions can affect infusion flow rates and pump pressures, thereby compromising the appropriate delivery of PN solutions to patients. The theoretical risk of glycosylation ...

The solution is MDM software, but what does it bring to your organization, is it worth the money, and will you get to exercise the level of control you need? What can you expect from an MDM ...

The Baylor Medicine Infusion Center offers patients an easy, attractive alternative to a hospital setting for receiving their infusion therapy, simplifying and expediting the process while providing ...

CRN‘s Solution Provider 500 ranks the top integrators, service providers and IT consultants in North America by services revenue. CRN breaks out which solution providers in each U.S. state and ...

This story appears in the December 2011 issue of National Geographic magazine. At the time of Jack the Ripper, a hard time for London, there lived in that city a mild-mannered stenographer named ...

He recently served as President and CEO of BioScrip, Inc. (“BioScrip”), the largest independent provider of infusion and home care management solutions, where he spearheaded the turnaround and ...

Baxter calculates forward-looking non-GAAP financial measures based on forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, forward-looking annual ...

Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion ...

pharmacokinetic profile supporting a 24-hour infusion, (3) stable PN solution infusion rate, (4) documented physical stability over at least 24 hours, and (5) documented chemical stability over at ...